Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors

Rongshi Li, Mathew P. Martin, Yan Liu, Binglin Wang, Ronil A. Patel, Jin Yi Zhu, Nan Sun, Roberta Pireddu, Nicholas J. Lawrence, Jiannong Li, Eric B. Haura, Shen Shu Sung, Wayne C. Guida, Ernst Schonbrunn, Said M. Sebti

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Using high concentration biochemical assays and fragment-based screening assisted by structure-guided design, we discovered a novel class of Rho-kinase inhibitors. Compound 18 was equipotent for ROCK1 (IC 50 = 650 nM) and ROCK2 (IC 50 = 670 nM), whereas compound 24 was more selective for ROCK2 (IC 50 = 100 nM) over ROCK1 (IC 50 = 1690 nM). The crystal structure of the compound 18-ROCK1 complex revealed that 18 is a type 1 inhibitor that binds the hinge region in the ATP binding site. Compounds 18 and 24 inhibited potently the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells.

Original languageEnglish (US)
Pages (from-to)2474-2478
Number of pages5
JournalJournal of Medicinal Chemistry
Volume55
Issue number5
DOIs
StatePublished - Mar 8 2012

Fingerprint

rho-Associated Kinases
Adenosine Triphosphate
Binding Sites
Phosphorylation
Breast Neoplasms
compound 18
N-dodecyl-L-lysine amide

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Li, R., Martin, M. P., Liu, Y., Wang, B., Patel, R. A., Zhu, J. Y., ... Sebti, S. M. (2012). Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. Journal of Medicinal Chemistry, 55(5), 2474-2478. https://doi.org/10.1021/jm201289r

Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. / Li, Rongshi; Martin, Mathew P.; Liu, Yan; Wang, Binglin; Patel, Ronil A.; Zhu, Jin Yi; Sun, Nan; Pireddu, Roberta; Lawrence, Nicholas J.; Li, Jiannong; Haura, Eric B.; Sung, Shen Shu; Guida, Wayne C.; Schonbrunn, Ernst; Sebti, Said M.

In: Journal of Medicinal Chemistry, Vol. 55, No. 5, 08.03.2012, p. 2474-2478.

Research output: Contribution to journalArticle

Li, R, Martin, MP, Liu, Y, Wang, B, Patel, RA, Zhu, JY, Sun, N, Pireddu, R, Lawrence, NJ, Li, J, Haura, EB, Sung, SS, Guida, WC, Schonbrunn, E & Sebti, SM 2012, 'Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors', Journal of Medicinal Chemistry, vol. 55, no. 5, pp. 2474-2478. https://doi.org/10.1021/jm201289r
Li, Rongshi ; Martin, Mathew P. ; Liu, Yan ; Wang, Binglin ; Patel, Ronil A. ; Zhu, Jin Yi ; Sun, Nan ; Pireddu, Roberta ; Lawrence, Nicholas J. ; Li, Jiannong ; Haura, Eric B. ; Sung, Shen Shu ; Guida, Wayne C. ; Schonbrunn, Ernst ; Sebti, Said M. / Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. In: Journal of Medicinal Chemistry. 2012 ; Vol. 55, No. 5. pp. 2474-2478.
@article{0bf0792d54dd4b0fa6deed5acdb9fc86,
title = "Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors",
abstract = "Using high concentration biochemical assays and fragment-based screening assisted by structure-guided design, we discovered a novel class of Rho-kinase inhibitors. Compound 18 was equipotent for ROCK1 (IC 50 = 650 nM) and ROCK2 (IC 50 = 670 nM), whereas compound 24 was more selective for ROCK2 (IC 50 = 100 nM) over ROCK1 (IC 50 = 1690 nM). The crystal structure of the compound 18-ROCK1 complex revealed that 18 is a type 1 inhibitor that binds the hinge region in the ATP binding site. Compounds 18 and 24 inhibited potently the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells.",
author = "Rongshi Li and Martin, {Mathew P.} and Yan Liu and Binglin Wang and Patel, {Ronil A.} and Zhu, {Jin Yi} and Nan Sun and Roberta Pireddu and Lawrence, {Nicholas J.} and Jiannong Li and Haura, {Eric B.} and Sung, {Shen Shu} and Guida, {Wayne C.} and Ernst Schonbrunn and Sebti, {Said M.}",
year = "2012",
month = "3",
day = "8",
doi = "10.1021/jm201289r",
language = "English (US)",
volume = "55",
pages = "2474--2478",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors

AU - Li, Rongshi

AU - Martin, Mathew P.

AU - Liu, Yan

AU - Wang, Binglin

AU - Patel, Ronil A.

AU - Zhu, Jin Yi

AU - Sun, Nan

AU - Pireddu, Roberta

AU - Lawrence, Nicholas J.

AU - Li, Jiannong

AU - Haura, Eric B.

AU - Sung, Shen Shu

AU - Guida, Wayne C.

AU - Schonbrunn, Ernst

AU - Sebti, Said M.

PY - 2012/3/8

Y1 - 2012/3/8

N2 - Using high concentration biochemical assays and fragment-based screening assisted by structure-guided design, we discovered a novel class of Rho-kinase inhibitors. Compound 18 was equipotent for ROCK1 (IC 50 = 650 nM) and ROCK2 (IC 50 = 670 nM), whereas compound 24 was more selective for ROCK2 (IC 50 = 100 nM) over ROCK1 (IC 50 = 1690 nM). The crystal structure of the compound 18-ROCK1 complex revealed that 18 is a type 1 inhibitor that binds the hinge region in the ATP binding site. Compounds 18 and 24 inhibited potently the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells.

AB - Using high concentration biochemical assays and fragment-based screening assisted by structure-guided design, we discovered a novel class of Rho-kinase inhibitors. Compound 18 was equipotent for ROCK1 (IC 50 = 650 nM) and ROCK2 (IC 50 = 670 nM), whereas compound 24 was more selective for ROCK2 (IC 50 = 100 nM) over ROCK1 (IC 50 = 1690 nM). The crystal structure of the compound 18-ROCK1 complex revealed that 18 is a type 1 inhibitor that binds the hinge region in the ATP binding site. Compounds 18 and 24 inhibited potently the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=84863237488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863237488&partnerID=8YFLogxK

U2 - 10.1021/jm201289r

DO - 10.1021/jm201289r

M3 - Article

C2 - 22272748

AN - SCOPUS:84863237488

VL - 55

SP - 2474

EP - 2478

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 5

ER -